

OIT Maintenance Protocols

Jennifer Ferguson DO

Division of Allergy/Immunology, Dept. of Internal Medicine, USF Morsani College of Medicine
Serving: USF Morsani College of Medicine and Public Health, Moffitt Cancer Center, Tampa General Hospital
James A Haley Veterans' Administration Hospital & Johns Hopkins All Children's Hospital, Tampa and St. Petersburg, Florida

Should maintenance dosing be similar to allergy shots?

- ▶ Year 1 – every 2-4 weeks
- ▶ Years 2-3 – every 4-6 weeks
- ▶ Years 4-5 – every 6-8 weeks

Dose frequency is reduced as long as patient is tolerating allergen exposure

No biomarker identified to correlate with stopping SCIT

- ▶ In vivo – skin test, allergen challenge
- ▶ Immunologic surrogate marker – ↓ specific IgE level, ↓ sIgE/total IgE ratio, ↑ IgG₄, ↑ serum IgA₁ and IgA₂, □ ↑ TGF-β
- ▶ Inflammatory markers – ↓ eos's, ↓ serum or nasal ECP, or ↓ ICAM-1
- ▶ Quality of life questionnaire

Senna G et al Curr Opin Allergy Clin Immunol 2011;11:375-80

OIT Course After Reaching Maintenance

- ▶ Year 1 - dosing 6-7 days/week
- ▶ Year 2 - dosing 5 days/week (weekend off?)
- ▶ Year 3 - dosing 4 day/week (QOD)
- ▶ Year 4 - dosing 3 days/week (M-W-F?)
- ▶ Year 5 - dosing 1-2 days/week

Once the patient reaches maintenance dose (M), they will be asked to dose daily until a high dose challenge in 2-3 months. If they pass the challenge, they can reduce the frequency of dosing to 6 days/week then follow-up annually with high dose challenge and blood testing to prove they remain protected despite less frequent dosing.

Annual High Dose Challenge

- ▶ **Purpose:** Clinical confirmation that annual dose reduction is still protective
- ▶ **Method:** One hour visit with single dose oral challenge
 - ▶ Foods: Peanut, tree nuts, sesame
 - ▶ ≤ 2 foods use 3-times home dose
 - ▶ > 2 foods use 2-times home dose (due to increased allergen load)
- ▶ **Exceptions:**
 - ▶ Staple foods (milk, egg, in some cases wheat)
 - ▶ Patients maintaining same dose/frequency

Annual High Dose Challenge Results


Frequency of dosing	% Pass Rate
5-7 days/wk	9/9 (100%)
3-4 days/wk	15/15 (100%)
1-2 days/wk	5/5 (100%)

Peanut OIT 2015-2018, 3-7 year Follow Up

N – 155
Median age – 7

Epi Reactors – 33 patients
(Median sIgE 87, age 9)

No Epi – 122 patients
(Median sIgE 31, age 6)



Maintenance Phase Troublemakers

- ▶ Patients who reacted in build up phase – 50% recidivism rate
- ▶ 12/155 (8%) reacted for 1st time in maintenance
 - ▶ 6 started as teens (median age 11)
 - ▶ 7 had only 1 reaction, 5 had from 2-5 reactions
 - ▶ 7 reacted within 1 year of maintenance, the later 5 only had 1 reaction
 - ▶ Dosing frequency at time of rxn. – daily for all, therefore:

Annual dose reduction strategies would have no impact on 1st time Epi reactions

Summary

- ▶ Prior Epi reactions are the best predictor of future reactions in our data
 - How should we treat them: reduce dose, consider SLIT???
- ▶ Maintenance reactions began before reducing dose frequency, leaving time as good a reason as any to guide adjusting dose frequency (like with SCIT)
- ▶ Confirmatory data from other sites needed
- ▶ Annual high dose challenge provides reassurance to the patient/family for accidental ingestion as dosing frequency declines